Suppr超能文献

可操纵鞘管对阵发性心房颤动导管消融的真实世界影响:INSIGHT研究

Real-World Impact of Steerable Sheaths for Paroxysmal Atrial Fibrillation Catheter Ablation: The INSIGHT Study.

作者信息

Okumura Yasuo, Kono Tsunesuke, Mizukami Akira, Inaba Osamu, Wakamatsu Yuji, Yamagishi Daisuke, Nakamura Satoshi, Arashiro Takumi, Sato Akira, Wang Yi, Kobori Atsushi

机构信息

Nihon University Itabashi Hospital, Tokyo, Japan.

Nagano Chuo Hospital, Nagano, Japan.

出版信息

J Cardiovasc Electrophysiol. 2025 Jun;36(6):1293-1302. doi: 10.1111/jce.16658. Epub 2025 Apr 1.

Abstract

INTRODUCTION

In atrial fibrillation (AF) ablation procedures, the CARTO VIZIGO Bidirectional Guiding Sheath has previously shown promising results in reducing fluoroscopy times without compromising clinical effectiveness or safety compared with non-steerable sheaths.

METHODS

This non-randomized, multicenter, retrospective cohort study (INSIGHT) aimed to determine the real-world impact of the VIZIGO sheath on procedural efficiency, clinical effectiveness, and safety in paroxysmal AF (PAF) catheter ablation. Consecutive adults who underwent de novo radiofrequency (RF) ablation for PAF with a non-VIZIGO sheath (January 2019-July 2021) or VIZIGO sheath (January 2020-July 2021) were included. Procedural characteristics, primary adverse events (PAEs), and 12-month effectiveness (freedom from repeat ablation or recurrent atrial arrhythmia) were evaluated.

RESULTS

Of 199 patients included (mean age, 69.7 years; 59.3% male), 97 had ablation with a VIZIGO sheath and 102 with a non-VIZIGO sheath. Significantly shorter mean times were achieved in the VIZIGO vs. non-VIZIGO group for time to left PVI (18.1 ± 7.5 vs. 19.9 ± 5.6 min, p = 0.046), right PVI (16.5 ± 6.1 vs. 23.1 ± 9.9 min, p < 0.001), total PVI (34.6 ± 9.7 vs. 42.9 ± 11.4 min, p = 0.002), and fluoroscopy time (7.3 ± 10.4 vs. 18.3 ± 13.3 min, p < 0.001). Mean fluoroscopy dose was significantly lower (45.9 ± 112.0 vs. 139.5 ± 251.5 mGy, p < 0.001) with VIZIGO vs. non-VIZIGO sheaths. Catheter stability was comparable between groups. PAE rates were similar in the VIZIGO (3.1%) and non-VIZIGO (4.9%) groups. Freedom from repeat ablation and recurrent atrial arrhythmia at 12 months were also similar in the two groups.

CONCLUSION

These real-world data demonstrate that use of the VIZIGO sheath in PAF ablation procedures allows for significantly lower fluoroscopy time and dose with significantly shorter PVI isolation time, without compromising acute and long-term effectiveness or safety.

摘要

引言

在房颤(AF)消融手术中,与不可操控鞘管相比,CARTO VIZIGO双向引导鞘管先前已显示出在减少透视时间方面有良好结果,且不影响临床有效性或安全性。

方法

这项非随机、多中心、回顾性队列研究(INSIGHT)旨在确定VIZIGO鞘管对阵发性房颤(PAF)导管消融手术效率、临床有效性和安全性的实际影响。纳入了连续接受首次PAF射频(RF)消融且使用非VIZIGO鞘管(2019年1月至2021年7月)或VIZIGO鞘管(2020年1月至2021年7月)的成年人。评估了手术特征、主要不良事件(PAE)和12个月的有效性(免于重复消融或复发性房性心律失常)。

结果

纳入的199例患者(平均年龄69.7岁;59.3%为男性)中,97例使用VIZIGO鞘管进行消融,102例使用非VIZIGO鞘管。与非VIZIGO组相比,VIZIGO组在到达左肺静脉隔离(PVI)时间(18.1±7.5对19.9±5.6分钟,p = 0.046)、右PVI时间(16.5±6.1对23.1±9.9分钟,p < 0.001)、总PVI时间(34.6±9.7对42.9±11.4分钟,p = 0.002)和透视时间(7.3±10.4对18.3±13.3分钟,p < 0.001)方面平均时间显著更短。使用VIZIGO鞘管时平均透视剂量显著更低(45.9±112.0对139.5±251.5 mGy,p < 0.001)。两组之间导管稳定性相当。VIZIGO组(3.1%)和非VIZIGO组(4.9%)的PAE发生率相似。两组在12个月时免于重复消融和复发性房性心律失常的情况也相似。

结论

这些实际数据表明,在PAF消融手术中使用VIZIGO鞘管可显著降低透视时间和剂量,PVI隔离时间显著缩短,且不影响急性和长期有效性或安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89c3/12160683/09009e67d2dc/JCE-36-1293-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验